Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans: Isolation, identification, quantification, and synthesis of urinary metabolites

Drug Metabolism and Disposition

Volumn 24, Issue 8, 1996, Pages 813-820

  Ensslin, Hartmut K ^a   Maurer, Hans H ^b   Gouzoulis, Euphrosyne ^c   Hermle, Leopold ^d   Kovar, Karl Artur ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d Department of Psychiatry ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; DRUG METABOLITE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE;

ARTICLE; CHEMICAL STRUCTURE; DRUG METABOLISM; DRUG SYNTHESIS; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INFRARED SPECTROMETRY; MASS SPECTROMETRY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACEMIC MIXTURE; URINALYSIS; URINARY EXCRETION;

3,4-METHYLENEDIOXYAMPHETAMINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, INFRARED; STEREOISOMERISM;

EID: 0029810759     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. H. Ensslin, K.-A. Kovar, and H. H. Maurer: Metabolismus von synthetischen Suchtstoffen der 2. Generation: die Metaboliten von Methylenedioxy-Etilamfetamin (MDE) im Urin des Menschen. Arch. Pharm. (Weinheim) 323, 661 (1990).
2. H. H. Maurer, H. Ensslin, and K.-A. Kovar: Zum Metabolismus von 3,4-Methylendioxyetilamfetamin (MDE) beim Menschen. Sucht 38, 109-110 (1992).
3. H. K. Ensslin: Metabolitenmuster und Bestimmung von 3,4-Methylendioxy-N-ethylamphetamin (MDE) im menschlichen Urin, Ph.D. thesis, University of Tuebingen (1994).
4. U. Braun, A. T. Shulgin, and G. Braun: Centrally active N-substituted analogues of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J. Pharm. Sci. 69, 192-195 (1980).
5. U. Braun, A. T. Shulgin, and G. Braun: Prüfung auf zentrale Aktivität und Analgesie von N-substituierten Analogen des Amphetamin-Derivates 3,4-Methylendioxyphenylisopropylamin. Arzneim. Forsch. 30, 825-830 (1980).
6. D. E. Nichols: Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens: identification of a new therapeutic class: entactogens. J. Psychoactive Drugs 18, 305-313 (1986).
7. R. G. Greer and R. Tolbert: The therapeutic use of MDMA. In "Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA" (S. J. Peroutka, ed.), pp. 21-35. Kluwer Academic Publishers Group, Dordrecht, The Netherlands, 1990.
8. J. Beck: The public health implications of MDMA use. In "Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA" (S. J. Peroutka, ed.), pp. 77-103. Kluwer Academic Publishers Group, Dordrecht, The Netherlands, 1990.
9. S. J. Peroutka: Recreational use of MDMA. In "Ecstasy: The Clinical, Pharmacological, and Neurotoxicological Effects of the Drug MDMA" (S. J. Peroutka, ed.), pp. 53-62. Kluwer Academic Publishers Group, Dordrecht, The Netherlands, 1990.
10. C. Singarajah and N. G. Lavies: An overdose of ecstasy. Anaesthesia 47, 686-687 (1992).
11. P. McGuire and T. Fahy: Flashbacks following MDMA. J. Psychiatry 160, 276-285 (1992).
12. J. A. Henry, K. J. Jeffreys, and S. Dawling: Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet 340, 384-387 (1992).
13. G. P. Dowling, E. T. McDonough III, and R. O. Bost: "Eve" and "ecstasy": a report of five deaths associated with the use of MDEA and MDMA. JAMA 257, 1615-1617 (1987).
14. E. Gouzoulis, D. Borchardt, and L. Hermle: A case of toxic psychosis induced by 'Eve' (3,4-methylenedioxyethylamphetamine). Arch. Gen. Psychiatry 50, 75 (1993).
15. M. T. Cregg and J. A. Tracey: Ecstasy abuse in Ireland. Ir. Med. J. 86, 118-120 (1993).
16. S. Manchada and M. J. Connolly: Cerebral infarction in association with ecstasy abuse. Postgrad. Med. J. 69, 874-875 (1993).
17. D. M. Stone, D. C. Stahl, G. R. Hanson, and J. W. Gibb: The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur. J. Pharmacol. 128, 41-48 (1986).
18. C. J. Schmidt, J. A. Levin, and W. Lovenberg: In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem. Pharmacol. 36, 747-755 (1987).
19. M. Johnson, G. R. Hanson, and J. W. Gibb: Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat. Biochem. Pharmacol. 36, 4085-4093 (1987).
20. D. L. Commins, G. Vosmer, R. M. Virus, W. L. Woolverton, C. R. Schuster, and L. S. Seiden: Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241, 338-344 (1987).
21. C. J. Schmidt: Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogues. Eur. J. Pharmacol. 136, 81-88 (1987).
22. M. Johnson, I. Elayan, G. R. Hanson, R. L. Foltz, J. W. Gibb, and H. K. Lim: Effects of 3,4-dihydroxymethamphetamine and 2,3,4-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotoninergic and dopaminergic systems. J. Pharmacol. Exp. Ther. 261, 447-453 (1992).
23. J. Brodkin, A. Malyala, and J. F. Nash: Effect of acute monamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity Pharmcol. Biochem. Behav. 45, 647-653 (1993).
24. W. Slikker, Jr., R. R. Holson, S. F. Ali, M. G. Kolta, M. G. Paule, A. C. Scallet, D. E. McMillan, J. R. Bailey, J. S. Hong, and F. M. Scalzo: Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10, 529-542 (1989).
25. G. A. Ricaurte and U. D. McCann: Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann. N. Y. Acad. Sci. 648, 371-382 (1992).
26. G. Ricaurte, G. Bryan, L. Strauss, L. Seiden, and C. Schuster: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science (Wash. DC) 229, 986-988 (1985).
27. T. R. Insel, G. Battaglia, J. N. Johannessen, S. Marra, and E. B. De Souza: 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J. Pharmacol. Exp. Ther. 249, 713-720 (1989).
28. S. F. Ali, G. D. Newport, A. C. Scallet, Z. Binienda, S. A. Ferguson, J. R. Bailey, M. G. Paule, and W. Slikker, Jr.: Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotoninergic depletion in the nonhuman primate. Neurotoxicol. Teratol. 15, 91-96 (1993).
29. D. M. Stone, M. Johnson, G. R. Hanson, and J. W. Gibb: A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur. J. Pharmacol. 134, 245-248 (1987).
30. G. A. Ricaurte, K. F. Finnegan, D. E. Nichols, L. E. DeLanney, I. Irwin, and J. W. Langston: 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur. J. Pharmacol. 137, 265-268 (1987).
31. M. Johnson, G. R. Hanson, and J. W. Gibb: Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system. Biochem. Pharmacol. 38, 4333-4338 (1989).
32. M. E. Molliver, E. O'Hearn, G. Battaglia, and E. B. De Souza: Direct intracerebral administration of MDA and MDMA does not produce serotonin neurotoxicity. Soc. Neurosci. Ahstr. 12, 1234 (1986).
33. H. H. Maurer, H. Ensslin, and K.-A. Kovar: On the metabolism of designer drugs. I. Studies on methylene-dioxy-etilamfetamine (MDE) in rats. Bull. Soc. Sci. Med. Grand-Duche Luxemb. 127, 467-471 (1990).
34. G. M. Marquardt, V. DiStefano, and L. L. Ling: Metabolism of 3,4-methylenedioxyamphetamine in the rat. Biochem. Pharmacol. 27, 1503-1505 (1978).
35. L. Y. Lin, Y. Kumagai, and A. K. Cho: Enzymatic and chemical demethylenation of (methylenedioxy)amphetamine and (methylenedioxy)-methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 5, 401-406 (1992).
36. G. M. Marquardt and V. DiStefano: The hepatic microsomal metabolism of 3,4-methylenedioxyamphetamine (MDA). Life Sci. 15, 1603-1610 (1974).
37. H. K. Lim and R. L. Foltz: In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem. Res. Toxicol. 1, 370-378 (1988).
38. M. Y. Yousif, R. L. Fitzgerald, N. Narasimhachari, J. A. Rosecrans, R. V. Blanke, and R. A. Glennon: Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. Drug Alcohol Depend. 26, 127-135 (1990).
39. R. Gollamudi, S. F. Ali, G. Lipe, G. Newport, P. Webb, M. Lopez, J. E. A. Leakey, M. Kolta, and W. Slikker, Jr.: Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. Neurotoxicology 10, 455-466 (1989).
40. H. K. Lim and R. L. Foltz: Identification of metabolites of 3,4-(methylenedioxy)methamphetamine in human urine. Chem. Res. Toxicol. 2, 142-143 (1989).
41. H. H. Maurer, M. R. Moeller, and K.-A. Kovar: On the metabolism of MDMA in humans. J. Chromatogr., in press.
42. C. Roesch: Synthetische Suchtstoffe: Vergleichende Analytik von Amphetaminderivaten, Ph.D. thesis, University of Tuebingen (1989).
43. K. S. Marshall and N. Castagnoli, Jr.: Absolute configuration of α-methyldopamine formed metabolically from α-methyldopa in man. J. Med. Chem. 16, 266-270 (1973).
44. C. B. Gairaud and G. R. Lappin: The synthesis of ω-nitrostyrenes. J. Org. Chem. 18, 1-3 (1953).
45. P. H. Morgan and A. H. Beckett: Synthesis of some N-oxygenated products of 3,4-dimethoxyamphetamine and its N-alkyl derivatives. Tetrahedron 31, 2595-2601 (1975).
46. R. A. Glennon, S. M. Liebowitz, and D. Leming-Doot: Demethyl analogues of psychoactive methoxyphenalkylamines: synthesis and serotonin receptor affinities. J. Med. Chem. 23, 990-994 (1980).
47. H. G. O. Becker et al., eds. "Organikum," ed. 16, pp. 423-424. VEB Deutscher Verlag der Wissenschaften, Berlin, 1986.
48. H. O. Bayer, H. Gotthardt, and R. Huisgen: Pyrrole aus Azlactonen und Acetylencarbonestern. Chem. Ber. 103, 2356-2367 (1970).
49. W. Van Brussel and C. F. Van Sumere: N-Acylamino acids and peptides. VI. A simple synthesis of N-acylglycines of the benzoyl- and cinnamyl type. Bull. Soc. Chim. Belg. 87, 791-796 (1978).
50. E. Gouzoulis, A. Steiger, H. K. Ensslin, K.-A. Kovar, and L. Hermle: Sleep EEG effects of 3,4-methylenedioxyethylamphetamine (MDE; "Eve") in healthy volunteers. Biol. Psychiatry 32, 1108-1117 (1992).
51. E. Gouzoulis, U. von Bardeleben, A. Rupp, K.-A. Kovar, and L. Hermle: Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology 8, 187-193 (1993).
52. H. H. Maurer: In "Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites" (K. Pfleger, H. H. Maurer, and A. Weber, eds.), ed. 2, part 1. VCH Publisher, Weinheim, 1992.
53. H. H. Maurer: Detection of anticonvulsants and their metabolites in urine within a general unknown analysis procedure using gas chromatography-mass spectrometry, Arch. Toxicol. 64, 554-561 (1990).
54. V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, C. T. Viswanathan, C. E. Cook, R. D. McDowall, K. A. Pittman, and S. Spector: Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Assoc. Off. Anal. Chemists Int. 75, 19A-26A (1992).
55. F. W. McLafferty and F. Turecek: "Interpretation of Mass Spectra," ed. 4. University Science Books, Mill Valley, CA, 1993.
56. H. M. Liebich and C. Foerst: Basic profiles of organic acids in urine. J. Chromatogr. 525, 1-14 (1990).
57. J. Caldwell: The metabolism of amphetamines in mammals. Drug Metab. Rev. 5, 219-280 (1976).